Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P13569: Variant p.Ser42Phe

Cystic fibrosis transmembrane conductance regulator
Gene: CFTR
Feedback?
Variant information Variant position: help 42 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Serine (S) to Phenylalanine (F) at position 42 (S42F, p.Ser42Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CF. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 42 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1480 The length of the canonical sequence.
Location on the sequence: help PILRKGYRQRLELSDIYQIP S VDSADNLSEKLEREWDRELA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         PILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELA

Gorilla                       PILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELA

                              PILIKGYRQRLELSDIYQVPSTDSADHLSEKLEREWDRELA

Rhesus macaque                PILRKGYRQRLELSDIYQIPSADSADNLSEKLEREWDRELA

Chimpanzee                    PILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELA

Mouse                         PILRKGYRHHLELSDIYQAPSADSADHLSEKLEREWDREQA

Rat                           PILRKGYRHHLELSDIYQAPSSDSADHLSEKLEREWDREQA

Pig                           PILRKGYRQRLELSDIYHISSSDSADNLSEKLEREWDRELA

Bovine                        PILKKGYRQRLELSDIYHISSSDSADNLSEKLEREWDRELA

Rabbit                        PILRKGYRQRLELSDIYQIPSADSADNLSEKLEREWDRELA

Sheep                         PILKKGYRQRLELSDIYHISSSDSADNLSEKLEREWDRELA

Horse                         PILRKGYRQRLELSDIYQIPSADSADNLSEKLEREWDRELV

Xenopus laevis                PILWKGYRQRLELSDIYQIHPGDSADNLSERLEREWDREVA

Zebrafish                     PIMRKGFKEKLRPSDVYQAPSQDAADILAERLEKEWDREVA
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1480 Cystic fibrosis transmembrane conductance regulator
Topological domain 1 – 77 Cytoplasmic
Helix 42 – 44



Literature citations
Identification of six novel CFTR mutations in a sample of Italian cystic fibrosis patients.
Ferec C.; Novelli G.; Verlingue C.; Quere I.; Dallapiccola B.; Audrezet M.P.; Mercier B.;
Mol. Cell. Probes 9:135-137(1995)
Cited for: VARIANTS CF PHE-42; LEU-117; ARG-139 AND GLU-1006;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.